NLSP nlspharma.com Net earnings per share for the last 12 months

NLSP (NLS Pharmaceutics Ltd.) - company brandmark

NLS Pharmaceutics AG is developing promising treatments for ADHD and narcolepsy, leveraging a strictly controlled drug distribution system. Analyzing the 12-month EPS trend chart on GURU.Markets, it is evident that -1.74 determines the latest valuation metric. The company is currently in the clinical testing stage without active cash flow, operating on its existing capital.

NLSP NLS Pharmaceutics AG Earnings per share for the trailing year (07/04/2022 - 10/31/2025)

NLS Pharmaceutics AG - analytical breakdowns and key metrics (NLSP)

- stock price and consensus target price:
Stock Price NLS Pharma|NLSP - Average Forecast Price
- market capitalization data:
Market Valuation NLS Pharmaceutics Ltd.|NLSP - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share NLS Pharmaceutics|NLSP - Accounting Value of Company|Market Value to Book Value Ratio nlspharma.com|NLSP - Company Assets
- debt level and financial liquidity data:
Debt to Equity NLS Pharmaceutics AG|NLSP - Long-Term Debt to Equity|Short-Term Debt to Equity NLS Pharma|NLSP - Company Cumulative Debt|Debts to Book Capitalization NLS Pharma|NLSP - Long-Term Indebtedness|Company Current Liabilities NLS Pharmaceutics|Quick Liquidity nlspharma.com
- earnings and multiples data:
NLSP - Company Profit|Expected Profit NLS Pharmaceutics AG|NLSP - Price to Earnings Ratio|Future Price to Earnings NLS Pharmaceutics Ltd.|NLSP - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio NLS Pharmaceutics|NLSP - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months NLS Pharmaceutics|NLSP - Earnings per one share for the last 12 months|Quarterly EPS earnings growth nlspharma.com|NLSP - Earnings per share increase in current year|Earnings growth forecast for next year NLS Pharmaceutics AG
- issuer revenue and sales details:
NLSP - Revenue and Sales Volume|Company Projected Revenue NLS Pharmaceutics|NLSP - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio NLS Pharmaceutics
Basic company analysis:NLS Pharmaceutics Ltd. (NLSP)
Mass-produced product of NLS Pharma

NLS Pharmaceutics AG (NLSP) is currently focusing on expanding its neuro-drug portfolio through strategic mergers and acquisitions. By analyzing the TTM net income per share on the GURU.Markets platform, an investor can see the final financial result distributed across the entire volume of the issue. This metric measures the real return on each share of capital over a rolling year. This chart reflects the business's ability to generate profit in an environment of expensive borrowed capital. However, to assess resilience to M&A transactions, this indicator should be compared with the level of debt load.

Analysis of competing companies

Jazz Pharmaceuticals Corp - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cytokinetics Inc|PTCT (PTC Therapeutics Inc) - Net earnings per share for the last 12 months|Scholar Rock Inc. (SRRK) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Centessa Pharmaceuticals|Net earnings per one share for the last twelve months dyne-tx.com DYN|Earnings per share for the last twelve months Edgewise Corp (EWTX)|RAPP - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Alumis Corp ALMS|Zevra Corp - Earnings per share for the last twelve months|CTNM - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Larimar Therapeutics|CAPR: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Entrada TRDA|Net earnings per share for the last 12 months PTHS|Net earnings per one share for the last twelve months medicinova.com MNOV|Net earnings per share (EPS TTM) SER|Earnings per share for the last twelve months BTAI (BioXcel Therapeutics)|Earnings per share for the last twelve months ProMIS Neurosciences, Inc. PMN|APUS (Apimeds) - Earnings per one share for the last 12 months|AEON - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Bionomics|HUGE (FSD Pharma) - Net earnings per share for the last 12 months|RETA: Earnings per share for the last four quarters